Kernal Biologics vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI-designed mRNA 2.0 therapeutics for in vivo CAR-T cancer and autoimmune therapy; $35.8M raised with Amgen Ventures backing advancing KR-335 toward IND filing.
About
Kernal Biologics is a clinical-stage biotech developing AI-designed mRNA therapeutics for cancer and autoimmune diseases — using machine learning to engineer cell-type-specific mRNA sequences that direct therapeutic payloads (including CAR-T gene programs) to the right cells in vivo, enabling off-the-shelf CAR-T cancer therapy without the individualized cell extraction and ex vivo manufacturing process that makes current CAR-T treatments cost $400,000+ and require weeks of production time. The Y Combinator-backed company has raised $35.8 million including a $25 million Series A led by Hummingbird Ventures with participation from Amgen Ventures.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.